Successfully transformed the organization from a two-country operation focused on development and manufacturing to a fully integrated company with a strong commercial engine bringing us closer to patients in over 120 countries
Divestment is part of BASF’s strategic portfolio optimization
Merck has also decided to end the favezelimab clinical development program
The company uses iPS cells to develop treatments for diseases relating to the kidney
The INTerpath-009 clinical trial demonstrates continued expansion of the INTerpath clinical program
Spread over 1.26 lakh sq ft building, the super-specialty eye hospital will perform 30,000 free eye surgeries annually for economically weaker sections
JB’s absolute Scope1 & Scope2 emissions reduced by 13.9 % in the last financial year, despite turnover increasing by 11%
Results from the open-label extension study of PHOTON demonstrate patients with diabetic macular edema (DME) randomized to Eylea 8 mg maintained visual and anatomic improvements at the end of three years
Buckley served as Chairman and Chief Executive Officer at Vanguard from 2018 until his retirement in 2024
The authorization of bortezomib will enhance the company’s ability to deliver advanced cancer solutions in Southeast Asia
Subscribe To Our Newsletter & Stay Updated
